NASDAQ: HUGE
CSE:HUGE | FRA:0K9A

FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance

June 1, 2022

< Older Post Newer Post >

Email Alerts

Receive most valuable updates straight into your inbox

Investor Inquiries

Please send investor relations inquiries to the following email:

[email protected]

General Inquiries

Please send all other inquiries to the following email:

[email protected]

image of word HUGE

© Copyright 2024 FSD Pharma.

All Right Reserved

Headquarters

55 University Ave. , Suite 1003
Toronto, ON, M5J 2H7 Canada

Contact Us

www.fsdpharma.com/contact

[email protected]

Share by: